Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL

Leukemia

Volumn 29, Issue 1, 2015, Pages 107-114

  Middleton, O ^a   Cosimo, E ^a   Dobbin, E ^b   McCaig, A M ^a,c   Clarke, C ^d   Brant, A M ^d   Leach, M T ^e   Michie, A M ^a   Wheadon, H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; FRESH FROZEN PLASMA; OFATUMUMAB; RITUXIMAB; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEFICIENCY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; BLOOD; CELL CULTURE; DEFICIENCY; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84920699926     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.146     Document Type: Article

References (28)

1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.
2. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016-3024.
3. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998; 48: 125-132.
4. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003; 278: 42427-42434.
5. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
6. Nabhan C, Coutre S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol 2007; 136: 379-392.
7. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-1755.
8. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111: 1094-1100.
9. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011; 118: 5126-5129.
10. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
11. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H et al. Characterization of new human CD20 monoclonal antibodies with potent cyto-lytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793-1800.
12. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177: 362-371.
13. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009; 183: 749-758.
14. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181: 822-832.
15. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
16. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
17. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444-449.
18. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE et al. Ritux-imab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-3288.
19. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530-2540.
20. Fust G, Czink E, Minh D, Miszlay Z, Varga L, Hollan SR. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol 1985; 60: 489-495.
21. Fust G, Miszlay Z, Czink E, Varga L, Paloczi K, Szegedi G et al. C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance. Immunol Lett 1987; 14: 255-259.
22. Heath ME, Cheson BD. Defective complement activity in chronic lymphocytic leukemia. Am J Hematol 1985; 19: 63-73.
23. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012; 188: 3532-3541.
24. Varga L, Czink E, Miszlai Z, Paloczi K, Banyai A, Szegedi G et al. Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1995; 99: 112-116.
25. Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 1994; 13: 203-214.
26. Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009; 1173: 865-873.
27. Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. Q J Med 2008; 101: 737-740.
28. Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pettinger AM et al. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol 2014; 192: 1620-1629.